Search

Your search keyword '"Magarotto, Valeria"' showing total 194 results
Start Over Author "Magarotto, Valeria"
194 results on '"Magarotto, Valeria"'

1. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

Author

Jaccard, Arnaud, Bridoux, Frank, Roeloffzen, Wilfried, Minnema, Monique C., Bergantim, Rui, Hájek, Roman, João, Cristina, Cibeira, M. Teresa, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Dimopoulos, Meletios A., Ravichandran, Sriram, Hegenbart, Ute, Agis, Hermine, Gros, Blanca, Asra, Aisha, Magarotto, Valeria, Cheliotis, Giorgos, Psarros, Giorgos, Sonneveld, Pieter, Wechalekar, Ashutosh, and Kastritis, Efstathios

Published
2024
Full Text
View/download PDF

2. Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe.

Author

Magarotto, Valeria, Thevenon, Julien, Morgan, Kate, Seldam, Silene ten, Iraqi, Wafae, Guillaume, Xavier, Leclerc, Marjorie, Graziani-Taugeron, Claire, Rault, Bleuenn, and Horchi, Dahbia

Subjects
*PATIENTS' attitudes, *INTRAVENOUS injections, *MULTIPLE myeloma, *DARATUMUMAB, *QUANTITATIVE research
Abstract

Purpose: To provide real-world data on patient perceptions and experiences with subcutaneous (SC) versus intravenous (IV) daratumumab. Patients and Methods: This was a cross-sectional, mixed-method (qualitative/quantitative) survey conducted in France, Germany, Spain and the United Kingdom involving multiple myeloma (MM) patients who switched from IV to SC daratumumab in the last 12 months (qualitative phase) or 24 months (quantitative phase [26 months in the UK]) prior to enrollment in the study. Results: Nine patients (mean age 65 years) participated in the qualitative phase and 113 patients (mean age 65.1 years) in the quantitative phase. Qualitative study results provided insights for the quantitative study and highlighted the benefits of switching from daratumumab IV to daratumumab SC as an improvement and a satisfactory change in patients' treatment journey. Quantitative survey showed that patients were significantly less anxious, stressed and nervous before SC injections than IV infusions (mean score: 1.3, 1.1, 1.4 versus 2.1, 2.0, 2.0 respectively, p< 0.001), and significantly more reassured, ready/well-prepared, usual self and relieved (mean score: 3.8, 4.3, 3.7, 3.6 versus 3.0, 3.6, 3.1, 3.0 respectively, p< 0.001). Immediately after SC first injection, 96.5% patients were feeling well or very well versus 77.9% immediately after IV first infusion (p< 0.001). 97.3% patients were satisfied with their SC treatment versus 89.4% for the IV injection (p< 0.001). Patients spent significantly less time in hospital for an SC injection of daratumumab than for an IV infusion, 1.5 hours and 5.0 hours respectively (p< 0.001). In the UK, the differences between the two administration forms were less visible, likely because of confounding factors including a longer time passed since the switch from the IV to the SC form and administration of the survey. Conclusion: In line with results from other studies, the SC form of daratumumab had less impact on patients' emotional burden than the IV form. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Description of Feelings, Perception, and Experience Before and After Switching from IV Daratumumab to the SC Form: A Mixed-Method, Cross-Sectional Survey in Multiple Myeloma Patients in Europe

Author

Magarotto,Valeria, Thevenon,Julien, Morgan,Kate, ten Seldam,Silene, Iraqi,Wafae, Guillaume,Xavier, Leclerc,Marjorie, Graziani-Taugeron,Claire, Rault,Bleuenn, Horchi,Dahbia, Magarotto,Valeria, Thevenon,Julien, Morgan,Kate, ten Seldam,Silene, Iraqi,Wafae, Guillaume,Xavier, Leclerc,Marjorie, Graziani-Taugeron,Claire, Rault,Bleuenn, and Horchi,Dahbia

Abstract

Valeria Magarotto,1 Julien Thevenon,2 Kate Morgan,3 Silene ten Seldam,3 Wafae Iraqi,4 Xavier Guillaume,5 Marjorie Leclerc,5 Claire Graziani-Taugeron,5 Bleuenn Rault,5 Dahbia Horchi5 1MD, Janssen-Cilag, Cologno Monzese, MI, Italy; 2Medical Affairs, Janssen Pharmaceuticals, Issy-les-Moulineaux, France; 3Myeloma Patients Europe, Brussels, Belgium; 4Patient Engagement, Janssen Pharmaceuticals, Issy-les-Moulineaux, France; 5RWE Data & Analytics, Oracle Life Sciences, Paris, FranceCorrespondence: Xavier Guillaume; Claire Graziani-Taugeron, Oracle France, 198 Avenue de France, Paris, 75013, France, Email xavier.guillaume@oracle.com; claire.graziani-taugeron@oracle.comPurpose: To provide real-world data on patient perceptions and experiences with subcutaneous (SC) versus intravenous (IV) daratumumab.Patients and Methods: This was a cross-sectional, mixed-method (qualitative/quantitative) survey conducted in France, Germany, Spain and the United Kingdom involving multiple myeloma (MM) patients who switched from IV to SC daratumumab in the last 12 months (qualitative phase) or 24 months (quantitative phase [26 months in the UK]) prior to enrollment in the study.Results: Nine patients (mean age 65 years) participated in the qualitative phase and 113 patients (mean age 65.1 years) in the quantitative phase. Qualitative study results provided insights for the quantitative study and highlighted the benefits of switching from daratumumab IV to daratumumab SC as an improvement and a satisfactory change in patients’ treatment journey. Quantitative survey showed that patients were significantly less anxious, stressed and nervous before SC injections than IV infusions (mean score: 1.3, 1.1, 1.4 versus 2.1, 2.0, 2.0 respectively, p< 0.001), and significantly more reassured, ready/well-prepared, usual self and relieved (mean score: 3.8, 4.3, 3.7, 3.6 versus 3.0, 3.6, 3.1, 3.0 respectively, p< 0.001). Immediately after SC first injection, 96.5% patients were feeling well or v

Published
2024

4. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Jaccard, Arnaud, Bridoux, Frank, Roeloffzen, Wilfried, Minnema, Monique C, Bergantim, Rui, Hájek, Roman, João, Cristina, Cibeira, M Teresa, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Dimopoulos, Meletios A, Ravichandran, Sriram, Hegenbart, Ute, Agis, Hermine, Gros, Blanca, Asra, Aisha, Magarotto, Valeria, Cheliotis, Giorgos, Psarros, Giorgos, Sonneveld, Pieter, Wechalekar, Ashutosh, Kastritis, Efstathios, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Jaccard, Arnaud, Bridoux, Frank, Roeloffzen, Wilfried, Minnema, Monique C, Bergantim, Rui, Hájek, Roman, João, Cristina, Cibeira, M Teresa, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Dimopoulos, Meletios A, Ravichandran, Sriram, Hegenbart, Ute, Agis, Hermine, Gros, Blanca, Asra, Aisha, Magarotto, Valeria, Cheliotis, Giorgos, Psarros, Giorgos, Sonneveld, Pieter, Wechalekar, Ashutosh, and Kastritis, Efstathios

Published
2024

5. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Author

Amorim, Sandy, Stathis, Anastasios, Gleeson, Mary, Iyengar, Sunil, Magarotto, Valeria, Leleu, Xavier, Morschhauser, Franck, Karlin, Lionel, Broussais, Florence, Rezai, Keyvan, Herait, Patrice, Kahatt, Carmen, Lokiec, François, Salles, Gilles, Facon, Thierry, Palumbo, Antonio, Cunningham, David, Zucca, Emanuele, and Thieblemont, Catherine

Published
2016
Full Text
View/download PDF

6. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Author

Magarotto, Valeria, Bringhen, Sara, Offidani, Massimo, Benevolo, Giulia, Patriarca, Francesca, Mina, Roberto, Falcone, Antonietta Pia, De Paoli, Lorenzo, Pietrantuono, Giuseppe, Gentili, Silvia, Musolino, Caterina, Giuliani, Nicola, Bernardini, Annalisa, Conticello, Concetta, Pulini, Stefano, Ciccone, Giovannino, Maisnar, Vladimír, Ruggeri, Marina, Zambello, Renato, Guglielmelli, Tommasina, Ledda, Antonio, Liberati, Anna Marina, Montefusco, Vittorio, Hajek, Roman, Boccadoro, Mario, and Palumbo, Antonio

Published
2016
Full Text
View/download PDF

7. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial

Author

Gay, Francesca, Oliva, Stefania, Petrucci, Maria Teresa, Conticello, Concetta, Catalano, Lucio, Corradini, Paolo, Siniscalchi, Agostina, Magarotto, Valeria, Pour, Luděk, Carella, Angelo, Malfitano, Alessandra, Petrò, Daniela, Evangelista, Andrea, Spada, Stefano, Pescosta, Norbert, Omedè, Paola, Campbell, Philip, Liberati, Anna Marina, Offidani, Massimo, Ria, Roberto, Pulini, Stefano, Patriarca, Francesca, Hajek, Roman, Spencer, Andrew, Boccadoro, Mario, and Palumbo, Antonio

Published
2015
Full Text
View/download PDF

8. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results from the Real-World, Retrospective EMN23 Study

Author

Jaccard, Arnaud, primary, Bridoux, Frank, additional, Roeloffzen, Wilfried, additional, Minnema, Monique, additional, Bergantim, Rui, additional, Hájek, Roman, additional, João, Cristina, additional, Cibeira, M. Teresa, additional, Palladini, Giovanni, additional, Schönland, Stefan, additional, Merlini, Giampaolo, additional, Milani, Paolo, additional, Dimopoulos, Meletios A., additional, Ravichandran, Sriram, additional, Hegenbart, Ute, additional, Agis, Hermine, additional, Gros, Blanca, additional, Asra, Aisha, additional, Magarotto, Valeria, additional, Cheliotis, Giorgos, additional, Psarros, Giorgos, additional, Sonneveld, Pieter, additional, Wechalekar, Ashutosh, additional, and Kastritis, Efstathios, additional

Published
2023
Full Text
View/download PDF

9. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Author

Bringhen, Sara, Petrucci, Maria Teresa, Larocca, Alessandra, Conticello, Concetta, Rossi, Davide, Magarotto, Valeria, Musto, Pellegrino, Boccadifuoco, Luana, Offidani, Massimo, Omedé, Paola, Gentilini, Fabiana, Ciccone, Giovannino, Benevolo, Giulia, Genuardi, Mariella, Montefusco, Vittorio, Oliva, Stefania, Caravita, Tommaso, Tacchetti, Paola, Boccadoro, Mario, Sonneveld, Pieter, and Palumbo, Antonio

Published
2014
Full Text
View/download PDF

10. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Author

Larocca, Alessandra, Montefusco, Vittorio, Bringhen, Sara, Rossi, Davide, Crippa, Claudia, Mina, Roberto, Galli, Monica, Marcatti, Magda, La Verde, Giacinto, Giuliani, Nicola, Magarotto, Valeria, Guglielmelli, Tommasina, Rota-Scalabrini, Delia, Omedé, Paola, Santagostino, Alberto, Baldi, Ileana, Carella, Angelo Michele, Boccadoro, Mario, Corradini, Paolo, and Palumbo, Antonio

Published
2013
Full Text
View/download PDF

11. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

Author

Gay, Francesca, Magarotto, Valeria, Crippa, Claudia, Pescosta, Norbert, Guglielmelli, Tommasina, Cavallo, Federica, Pezzatti, Sara, Ferrari, Samantha, Liberati, Anna Marina, Oliva, Stefania, Patriarca, Francesca, Offidani, Massimo, Omedé, Paola, Montefusco, Vittorio, Petrucci, Maria Teresa, Giuliani, Nicola, Passera, Roberto, Pietrantuono, Giuseppe, Boccadoro, Mario, Corradini, Paolo, and Palumbo, Antonio

Published
2013
Full Text
View/download PDF

12. Lenalidomide and low‐dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials

Author

Gentile, Massimo, Magarotto, Valeria, Offidani, Massimo, Musto, Pellegrino, Bringhen, Sara, Teresa Petrucci, Maria, Gay, Francesca, Larocca, Alessandra, Uccello, Giuseppina, Petrungaro, Annamaria, Vigna, Ernesto, Greco, Rosa, Grazia Recchia, Anna, Tripepi, Giovanni, Ria, Roberto, Di Raimondo, Francesco, Palumbo, Antonio, and Morabito, Fortunato

Published
2017
Full Text
View/download PDF

13. Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results

Author

Palumbo, Antonio, Falco, Patrizia, Falcone, Antonietta, Benevolo, Giulia, Canepa, Letizia, Gay, Francesca, Larocca, Alessandra, Magarotto, Valeria, Gozzetti, Alessandro, Luraschi, Annalisa, Morabito, Fortunato, Nozza, Andrea, Knight, Robert D., Zeldis, Jerome B., Boccadoro, Mario, and Petrucci, Maria Teresa

Published
2009
Full Text
View/download PDF

14. The Use of Ibrutinib in Italian CLL Patients Treated in a Real-World Setting (EVIDENCE): A Preliminary Report

Author

Molica, Stefano, primary, Scalzulli, Potito Rosario, additional, Scarfo, Lydia, additional, Guarini, Attilio, additional, Murru, Roberta, additional, Sportoletti, Paolo, additional, Frigeri, Ferdinando, additional, Albano, Francesco, additional, Di Renzo, Nicola, additional, Sanna, Alessandro, additional, Innocenti, Idanna, additional, Massaia, Massimo, additional, Coscia, Marta, additional, Pennese, Elsa, additional, Patti, Caterina, additional, Reda, Gianluigi, additional, Tafuri, Agostino, additional, Grugnetti, Anna, additional, Magarotto, Valeria, additional, and Mauro, Francesca Romana, additional

Published
2021
Full Text
View/download PDF

15. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

Author

Morabito, Fortunato, Bringhen, Sara, Larocca, Alessandra, Wijermans, Pierre, Victoria Mateos, Maria, Gimsing, Peter, Mazzone, Carla, Gottardi, Daniela, Omedè, Paola, Zweegman, Sonja, José Lahuerta, Juan, Zambello, Renato, Musto, Pellegrino, Magarotto, Valeria, Schaafsma, Martijn, Oriol, Albert, Juliusson, Gunnar, Cerrato, Chiara, Catalano, Lucio, Gentile, Massimo, Isabel Turel, Ana, Marina Liberati, Anna, Cavalli, Maide, Rossi, Davide, Passera, Roberto, Rosso, Stefano, Beksac, Meral, Cavo, Michele, Waage, Anders, San Miguel, Jesus, Boccadoro, Mario, Sonneveld, Pieter, Palumbo, Antonio, and Offidani, Massimo

Published
2014
Full Text
View/download PDF

16. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

Author

Rocci, Alberto, Gambella, Manuela, Aschero, Simona, Baldi, Ileana, Trusolino, Livio, Cavallo, Federica, Gay, Francesca, Larocca, Alessandra, Magarotto, Valeria, Omedè, Paola, Isaia, Gianluca, Bertotti, Andrea, Liberati, Anna M., Catalano, Lucio, De Rosa, Luca, Musto, Pellegrino, Vallone, Roberto, Falcone, Antonietta, Drandi, Daniela, Ladetto, Marco, Comoglio, Paolo M., Boccadoro, Mario, and Palumbo, Antonio

Published
2014
Full Text
View/download PDF

19. The Activity of Spanish and Italian Myeloma Groups

Author

Boccadoro, Mario, Palumbo, Antonio, Cavo, Michele, Di Raimondo, Francesco, Bringhen, Sara, Magarotto, Valeria, Larocca, Alessandra, Mateos, Maria Victoria, Lahuerta, Juan José, Cibeira, Teresa M., Martínez, J., Rosiñol, Laura, Bladé, Joan, and San Miguel, Jesús F.

Published
2009

21. Multiple Myeloma

Author

Bringhen, Sara, Avonto, Ilaria, Magarotto, Valeria, Boccadoro, Mario, and Palumbo, Antonio

Published
2007

23. Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase Ill Trial

Author

Gay, Francesca, Magarotto, Valeria, Petrucci, Maria Teresa, Di Raimondo, Francesco, Pour, Ludek, Caravita, Tommaso, Scudla, Vlastimil, Cafro, Anna Maria, Liberati, Anna Marina, Spada, Stefano, Vladimir, Maisnar, Pescosta, Norbert, Ria, Roberto, Offidani, Massimo, Bringhen, Sara, Bernardini, Annalisa, Patriarca, Francesca, Corradini, Paolo, Foa, Roberto, Cascavilla, Nicola, Catalano, Lucio, Spencer, Andrew, Roman Hajek, Boccadoro, Mario, and Palumbo, Antonio

Published
2015

24. Gammopatie monoclonali

Author

Boccadoro, Mario, Gay, Francesca Maria, Larocca, Alessandra, Magarotto, Valeria, and Palumbo, Antonio

Published
2015

25. A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients

Author

Bringhen, Sara, primary, Magarotto, Valeria, additional, Liberati, Anna Marina, additional, Belotti, Angelo, additional, Larocca, Alessandra, additional, Gilestro, Milena, additional, Bonello, Francesca, additional, Gaidano, Gianluca, additional, Bertazzoni, Paola, additional, Stocchi, Raffaella, additional, Ribolla, Rossella, additional, Di Sano, Chiara, additional, Patriarca, Francesca, additional, Passera, Roberto, additional, De Paoli, Lorenzo, additional, Oliva, Stefania, additional, Cafro, Anna Maria, additional, Sonneveld, Pieter, additional, Palumbo, Antonio, additional, and Boccadoro, Mario, additional

Published
2016
Full Text
View/download PDF

26. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).

Author

Attal, Michel, primary, Palumbo, Antonio, additional, Holstein, Sarah A., additional, Lauwers-Cances, Valerie, additional, Petrucci, Maria Teresa, additional, Richardson, Paul G., additional, Hulin, Cyrille, additional, Tosi, Patrizia, additional, Anderson, Kenneth Carl, additional, Caillot, Denis, additional, Magarotto, Valeria, additional, Moreau, Philippe, additional, Marit, Gerald, additional, Yu, Zhinuan, additional, and McCarthy, Philip L., additional

Published
2016
Full Text
View/download PDF

27. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Author

Monika, Engelhardt, Evangelos, Terpos, Martina, Kleber, Gay, Francesca Maria, Ralph, Wäsch, Gareth, Morgan, Michele, Cavo, Niels van de Donk, Andreas, Beilhack, Bruno, Benedetto, Hans Erik Johnsen, Roman, Hajek, Christoph, Driessen, Heinz, Ludwig, Meral, Beksac, Boccadoro, Mario, Christian, Straka, Sara, Brighen, Martin, Gramatzki, Larocca, Alessandra, Henk, Lokhorst, Magarotto, Valeria, Fortunato, Morabito, Meletios, A Dimopoulos, Hermann, Einsele, Pieter, Sonneveld, Palumbo, Antonio, European Myeloma Network, Plastic and Reconstructive Surgery and Hand Surgery, and Hematology

Subjects
Oncology, medicine.medical_specialty, business.industry, Bortezomib, medicine.medical_treatment, Hematopoietic Stem Cell Transplantation, Hematology, Hematopoietic stem cell transplantation, medicine.disease, Surgery, Thalidomide, Transplantation, Guideline Article, Autologous stem-cell transplantation, Clinical Trials, Phase III as Topic, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, business, Autografts, Multiple Myeloma, Dexamethasone, Multiple myeloma, medicine.drug, Lenalidomide
Abstract

Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and for cytogenetically defined high- versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease and preferably in the context of a clinical trial (2B). Thalidomide (1B) or lenalidomide (1A) maintenance increases progression-free survival and possibly overall survival (2B). Bortezomib-based regimens are a valuable consolidation option, especially for patients who failed excellent response after autologous stem cell transplantation (2A). Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care for transplant-ineligible patients (1A). Melphalan-prednisone-lenalidomide with lenalidomide maintenance increases progression-free survival, but overall survival data are needed. New data from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached its primary end point of a statistically significant improvement in progression-free survival as compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B).

Published
2014
Full Text
View/download PDF

30. Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients

Author

Mina, Roberto, primary, Larocca, Alessandra, additional, Offidani, Massimo, additional, Bringhen, Sara, additional, Caravita, Tommaso, additional, Magarotto, Valeria, additional, Pantani, Lucia, additional, Di Raimondo, Francesco, additional, Bosi, Alberto, additional, Vincelli, Iolanda D., additional, Tacchetti, Paola, additional, Gaidano, Gianluca, additional, Grandi, Sonia, additional, Musolino, Caterina, additional, Cerrato, Chiara, additional, Pour, Ludek, additional, Astolfi, Monica, additional, Rossi, Giuseppe, additional, Rossini, Fausto, additional, Petrucci, Maria T., additional, Ria, Roberto, additional, Pezzi, Annalisa, additional, Hajek, Roman, additional, Cavo, Michele, additional, Spencer, Andrew, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2015
Full Text
View/download PDF

31. Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial

Author

Gay, Francesca, primary, Magarotto, Valeria, additional, Petrucci, Maria Teresa, additional, Di Raimondo, Francesco, additional, Pour, Luděk, additional, Caravita, Tommaso, additional, Scudla, Vlastimil, additional, Cafro, Anna Maria, additional, Liberati, Anna Marina, additional, Spada, Stefano, additional, Vladimir, Maisnar, additional, Pescosta, Norbert, additional, Ria, Roberto, additional, Offidani, Massimo, additional, Bringhen, Sara, additional, Bernardini, Annalisa, additional, Patriarca, Francesca, additional, Corradini, Paolo, additional, Foà, Roberto, additional, Cascavilla, Nicola, additional, Catalano, Lucio, additional, Spencer, Andrew, additional, Hajek, Roman, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2015
Full Text
View/download PDF

32. Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Author

Voorhees, Peter M., primary, Magarotto, Valeria, additional, Sonneveld, Pieter, additional, Plesner, Torben, additional, Mellqvist, Ulf-Henrik, additional, Paba-Prada, Claudia E., additional, Byrne, Catriona, additional, Harmenberg, Johan, additional, Nordstrom, Eva, additional, Palumbo, Antonio, additional, and Richardson, Paul, additional

Published
2015
Full Text
View/download PDF

33. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Author

Engelhardt, Monika Terpos, Evangelos Kleber, Martina Gay, Francesca Waesch, Ralph Morgan, Gareth Cavo, Michele van de Donk, Niels Beilhack, Andreas Bruno, Benedetto Johnsen, Hans Erik Hajek, Roman Driessen, Christoph Ludwig, Heinz and Beksac, Meral Boccadoro, Mario Straka, Christian Brighen, Sara Gramatzki, Martin Larocca, Alessandra Lokhorst, Henk and Magarotto, Valeria Morabito, Fortunato Dimopoulos, Meletios A. Einsele, Hermann Sonneveld, Pieter Palumbo, Antonio and European Myeloma Network and Engelhardt, Monika Terpos, Evangelos Kleber, Martina Gay, Francesca Waesch, Ralph Morgan, Gareth Cavo, Michele van de Donk, Niels Beilhack, Andreas Bruno, Benedetto Johnsen, Hans Erik Hajek, Roman Driessen, Christoph Ludwig, Heinz and Beksac, Meral Boccadoro, Mario Straka, Christian Brighen, Sara Gramatzki, Martin Larocca, Alessandra Lokhorst, Henk and Magarotto, Valeria Morabito, Fortunato Dimopoulos, Meletios A. Einsele, Hermann Sonneveld, Pieter Palumbo, Antonio and European Myeloma Network

Abstract

Multiple myeloma management has undergone profound changes in the past thanks to advances in our understanding of the disease biology and improvements in treatment and supportive care approaches. This article presents recommendations of the European Myeloma Network for newly diagnosed patients based on the GRADE system for level of evidence. All patients with symptomatic disease should undergo risk stratification to classify patients for International Staging System stage (level of evidence: 1A) and for cytogenetically defined high-versus standard-risk groups (2B). Novel-agent-based induction and up-front autologous stem cell transplantation in medically fit patients remains the standard of care (1A). Induction therapy should include a triple combination of bortezomib, with either adriamycin or thalidomide and dexamethasone (1A), or with cyclophosphamide and dexamethasone (2B). Currently, allogeneic stem cell transplantation may be considered for young patients with high-risk disease and preferably in the context of a clinical trial (2B). Thalidomide (1B) or lenalidomide (1A) maintenance increases progression-free survival and possibly overall survival (2B). Bortezomib-based regimens are a valuable consolidation option, especially for patients who failed excellent response after autologous stem cell transplantation (2A). Bortezomib-melphalan-prednisone or melphalan-prednisone-thalidomide are the standards of care for transplant-ineligible patients (1A). Melphalan-prednisone-lenalidomide with lenalidomide maintenance increases progression-free survival, but overall survival data are needed. New data from the phase III study (MM-020/IFM 07-01) of lenalidomide-low-dose dexamethasone reached its primary end point of a statistically significant improvement in progression-free survival as compared to melphalan-prednisone-thalidomide and provides further evidence for the efficacy of lenalidomide-low-dose dexamethasone in transplant-ineligible patients (2B).

Published
2014

34. Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients:A retrospective case-matched study

Author

Morabito, Fortunato, Bringhen, Sara, Larocca, Alessandra, Wijermans, Pierre, Victoria Mateos, Maria, Gimsing, Peter, Mazzone, Carla, Gottardi, Daniela, Omedè, Paola, Zweegman, Sonja, José Lahuerta, Juan, Zambello, Renato, Musto, Pellegrino, Magarotto, Valeria, Schaafsma, Martijn, Oriol, Albert, Juliusson, Gunnar, Cerrato, Chiara, Catalano, Lucio, Gentile, Massimo, Isabel Turel, Ana, Marina Liberati, Anna, Cavalli, Maide, Rossi, Davide, Passera, Roberto, Rosso, Stefano, Beksac, Meral, Cavo, Michele, Waage, Anders, San Miguel, Jesus, Boccadoro, Mario, Sonneveld, Pieter, Palumbo, Antonio, Offidani, Massimo, Morabito, Fortunato, Bringhen, Sara, Larocca, Alessandra, Wijermans, Pierre, Victoria Mateos, Maria, Gimsing, Peter, Mazzone, Carla, Gottardi, Daniela, Omedè, Paola, Zweegman, Sonja, José Lahuerta, Juan, Zambello, Renato, Musto, Pellegrino, Magarotto, Valeria, Schaafsma, Martijn, Oriol, Albert, Juliusson, Gunnar, Cerrato, Chiara, Catalano, Lucio, Gentile, Massimo, Isabel Turel, Ana, Marina Liberati, Anna, Cavalli, Maide, Rossi, Davide, Passera, Roberto, Rosso, Stefano, Beksac, Meral, Cavo, Michele, Waage, Anders, San Miguel, Jesus, Boccadoro, Mario, Sonneveld, Pieter, Palumbo, Antonio, and Offidani, Massimo

Abstract

Novel agents in combination with melphalan and prednisone (MP) significantly improved progression-free survival (PFS) and overall survival (OS) in multiple myeloma (MM). Randomized trials comparing MP plus bortezomib (VMP) versus MP plus thalidomide (MPT) are lacking. Nine hundred and fifty-six elderly (>65 years) newly diagnosed MM patients from six European randomized trials were retrospectively analyzed and matched for age, albumin, and beta2-microglobulin at diagnosis, 296 patients were selected from the VMP groups, and 294 from MPT. Complete response rate was 21% in the VMP patients and 13% in the MPT patients (P = 0.007). After a median follow-up of 34 months (range, 1-92), VMP significantly prolonged both PFS (median 32.5 vs. 22.9 months, HR 0.65; 95% CI 0.52-0.82; P < 0.001) and OS (median 79.7 vs. 45.1 months, HR 0.44; 95% CI 0.32-0.59; P < 0.001) in comparison with MPT. The benefit in terms of OS of the VMP group was quite similar among patients with different risk factors defined by sex, ISS, ECOG performance status, or serum creatinine but not among patients ≥ 75 years. Multivariate analysis confirmed that VMP was an independent predictor of longer PFS and OS. In a control-case matched analysis, PFS and OS were prolonged in patients who received VMP in comparison with those treated with MPT.

Published
2014

35. Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study

Author

Magarotto, Valeria, primary, Bringhen, Sara, additional, Musto, Pellegrino, additional, Offidani, Massimo, additional, Liberati, Anna Marina, additional, Pour, Ludek, additional, Benevolo, Giulia, additional, Genuardi, Mariella, additional, Musolino, Caterina, additional, Ledda, Antonio, additional, Oddolo, Daniela, additional, De Paoli, Lorenzo, additional, Patriarca, Francesca, additional, Falcone, Antonietta Pia, additional, Caratozzolo, Isola, additional, Zambello, Renato, additional, Cavalli, Maide, additional, Gentili, Silvia, additional, Hajek, Roman, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2014
Full Text
View/download PDF

36. The Presence of FDG PET/CT Focal, Not Osteolytic, Lesion(s) Identifies a Sub-Group of Patients with Smoldering Multiple Myeloma with High-Risk of Progression into Symptomatic Disease

Author

Zamagni, Elena, primary, Nanni, Cristina, additional, Gay, Francesca, additional, Pezzi, Annalisa, additional, Bellò, Marilena, additional, Rambaldi, Ilaria, additional, Tacchetti, Paola, additional, Brioli, Annamaria, additional, Pantani, Lucia, additional, Magarotto, Valeria, additional, Zannetti, Beatrice Anna, additional, Menga, Massimo, additional, Marzocchi, Giulia, additional, Terragna, Carolina, additional, Mancuso, Katia, additional, Palumbo, Antonio, additional, Fanti, Stefano, additional, and Cavo, Michele, additional

Published
2014
Full Text
View/download PDF

37. Abstract CT231: BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies

Author

Herait, Patrice E., primary, Berthon, Celine, additional, Thieblemont, Catherine, additional, Raffoux, Emmanuel, additional, Magarotto, Valeria, additional, Stathis, Anastasios, additional, Thomas, Xavier, additional, Leleu, Xavier, additional, Gomez-Roca, Carlos, additional, Odore, Elodie, additional, Roumier, Christophe, additional, Bourdel, Fabrice, additional, Quesnel, Bruno, additional, Zucca, Emanuele, additional, Michallet, Mauricette, additional, Recher, Christian, additional, Cvitkovic, Esteban, additional, Rezai, Keyvan, additional, Preudhomme, Claude, additional, Facon, Thierry, additional, Palumbo, Antonio, additional, and Dombret, Herve, additional

Published
2014
Full Text
View/download PDF

38. Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Author

Palumbo, Antonio, primary, Bringhen, Sara, additional, Larocca, Alessandra, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Magarotto, Valeria, additional, Patriarca, Francesca, additional, Levi, Anna, additional, Benevolo, Giulia, additional, Vincelli, Iolanda Donatella, additional, Grasso, Mariella, additional, Franceschini, Luca, additional, Gottardi, Daniela, additional, Zambello, Renato, additional, Montefusco, Vittorio, additional, Falcone, Antonietta Pia, additional, Omedé, Paola, additional, Marasca, Roberto, additional, Morabito, Fortunato, additional, Mina, Roberto, additional, Guglielmelli, Tommasina, additional, Nozzoli, Chiara, additional, Passera, Roberto, additional, Gaidano, Gianluca, additional, Offidani, Massimo, additional, Ria, Roberto, additional, Petrucci, Maria Teresa, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, and Cavo, Michele, additional

Published
2014
Full Text
View/download PDF

39. Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age

Author

Larocca, Alessandra, primary, Cavallo, Federica, additional, Magarotto, Valeria, additional, Offidani, Massimo, additional, Federico, Vincenzo, additional, Innao, Vanessa, additional, Falcone, Antonietta Pia, additional, Romano, Alessandra, additional, Caravita, Tommaso, additional, Rossi, Davide, additional, Mansueto, Giovanna, additional, Mina, Roberto, additional, Nozzoli, Chiara, additional, Benevolo, Giulia, additional, Guglielmelli, Tommasina, additional, Liberati, Anna Marina, additional, Derudas, Daniele, additional, Oliva, Stefania, additional, Morabito, Fortunato, additional, Carella, Angelo Michele, additional, Gentili, Silvia, additional, Saraci, Elona, additional, Petrucci, Maria Teresa, additional, Sonneveld, Pieter, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2013
Full Text
View/download PDF

40. Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma

Author

Pichiorri, Flavia, primary, Rocci, Alberto, additional, Hofmeister, Craig C, additional, Geyer, Susan, additional, Talabere, Tiffany, additional, Gambella, Massimiliano, additional, Cascione, Luciano, additional, Stiff, Andrew, additional, Benson, Don M., additional, Efebera, Yvonne A, additional, Dirisala, Vijaya, additional, Smith, Emily M, additional, Omedè, Paola, additional, Musto, Pellegrino, additional, Rossi, Davide, additional, Gentili, Silvia, additional, Uccello, Giuseppina, additional, Ria, Roberto, additional, Benevolo, Giulia, additional, Bringhen, Sara, additional, Callea, Vincenzo, additional, Weiss, Brendan M, additional, Ferro, Alfredo, additional, Magarotto, Valeria, additional, Alder, Hansjuerg, additional, Byrd, John C., additional, Boccadoro, Mario, additional, Marcucci, Guido, additional, and Palumbo, Antonio, additional

Published
2013
Full Text
View/download PDF

41. A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients

Author

Palumbo, Antonio, primary, Magarotto, Valeria, additional, Bringhen, Sara, additional, Offidani, Massimo, additional, Pietrantuono, Giuseppe, additional, Liberati, Anna Marina, additional, Benevolo, Giulia, additional, Ledda, Antonio, additional, Gilestro, Milena, additional, Galli, Monica, additional, Patriarca, Francesca, additional, Genuardi, Mariella, additional, Giuliani, Nicola, additional, Zambello, Renato, additional, Zdenek, Adam, additional, La Fauci, Alessia, additional, Corradini, Paolo, additional, Falcone, Antonietta Pia, additional, Musolino, Caterina, additional, Rossi, Davide, additional, Caraffa, Patrizia, additional, Musto, Pellegrino, additional, Cavallo, Federica, additional, Hajek, Roman, additional, and Boccadoro, Mario, additional

Published
2013
Full Text
View/download PDF

44. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.

Author

Magarotto, Valeria, Salvini, Marco, Bonello, Francesca, Bringhen, Sara, and Palumbo, Antonio

Subjects
*MULTIPLE myeloma treatment, *MONOCLONAL antibodies, *PROTEASOME inhibitors, *DRUG efficacy, *PROGRESSION-free survival
Abstract

Novel agents, such as immunomodulantory drugs (IMiDs) and proteasome inhibitors (PI), have significantly improved overall survival of multiple myeloma (MM) patients. Yet, MM remains an incurable disease, relapse inevitably occurs and patients tend to become resistant to subsequent treatments. This led to the evaluation of new treatment strategies. The recent development of monoclonal antibodies is changing the treatment algorithm of MM by increasing the therapeutic armamentarium. Elotuzumab and Daratumumab were shown to be very effective and are likely to be soon approved by the FDA. Other antibodies are in pre-clinical or early clinical phases of evaluation and further investigation and more robust data are needed. This review will give an overview of the most active monoclonal antibodies against MM. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

45. Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients

Author

Palumbo, Antonio, primary, Bringhen, Sara, additional, Rossi, Davide, additional, Cavalli, Maide, additional, Ria, Roberto, additional, Gentilini, Silvia, additional, Patriarca, Francesca, additional, Nozzoli, Chiara, additional, Levi, Anna, additional, Guglielmelli, Tommasina, additional, Benevolo, Giulia, additional, Vincelli, Donatella, additional, Baldini, Luca, additional, Morabito, Fortunato, additional, Grasso, Mariella, additional, Marasca, Roberto, additional, Rizzo, Manuela, additional, Pautasso, Chiara, additional, Falcone, Antonietta Pia, additional, Gottardi, Daniela, additional, Montefusco, Vittorio, additional, Musolino, Caterina, additional, Cangialosi, Clotilde, additional, Mansueto, Giovanna, additional, Liberati, Anna Marina, additional, Magarotto, Valeria, additional, Omedè, Paola, additional, Musto, Pellegrino, additional, Petrucci, Maria Teresa, additional, and Boccadoro, Mario, additional

Published
2012
Full Text
View/download PDF

46. Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

Author

Palumbo, Antonio, primary, Cavo, Michele, additional, Bringhen, Sara, additional, Zamagni, Elena, additional, Romano, Alessandra, additional, Patriarca, Francesca, additional, Rossi, Davide, additional, Gentilini, Fabiana, additional, Crippa, Claudia, additional, Galli, Monica, additional, Nozzoli, Chiara, additional, Ria, Roberto, additional, Marasca, Roberto, additional, Montefusco, Vittorio, additional, Baldini, Luca, additional, Elice, Francesca, additional, Callea, Vincenzo, additional, Pulini, Stefano, additional, Carella, Angelo M., additional, Zambello, Renato, additional, Benevolo, Giulia, additional, Magarotto, Valeria, additional, Tacchetti, Paola, additional, Pescosta, Norbert, additional, Cellini, Claudia, additional, Polloni, Claudia, additional, Evangelista, Andrea, additional, Caravita, Tommaso, additional, Morabito, Fortunato, additional, Offidani, Massimo, additional, Tosi, Patrizia, additional, and Boccadoro, Mario, additional

Published
2011
Full Text
View/download PDF

47. miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients

Author

Andrew Stiff, Alberto Rocci, Craig C. Hofmeister, Paola Omedè, Susan Geyer, Sara Bringhen, Luciano Cascione, Anissa Bingman, Manuela Gambella, Federica Cavallo, Luciana De Luca, Jingwen Guan, Alessandra Larocca, Jacqueline Corry, Francesca Gay, Yvonne A Efebera, Uccello G, Don M. Benson, Tiffany Talabere, Kevin Murnan, Magarotto Valeria, Mario Boccadoro, Carlo M. Croce, Antonio Palumbo, and Flavia Pichiorri

Subjects
Pathology, medicine.medical_specialty, Creatinine, biology, Beta-2 microglobulin, Myeloma protein, Immunology, C-reactive protein, Cell Biology, Hematology, medicine.disease, Biochemistry, Pathogenesis, chemistry.chemical_compound, medicine.anatomical_structure, chemistry, medicine, biology.protein, Bone marrow, Precordial catch syndrome, Multiple myeloma
Abstract

Abstract 2921 Background: Multiple myeloma (MM) is a clonal B-cell malignancy characterized by the aberrant expansion of clonal plasma cells (PCs) within the bone marrow. Malignant PCs produce intact or partial monoclonal immunoglobulin (M protein) and cause organ damage. More than 20,000 new cases of multiple myeloma (MM) are diagnosed every year in the US with approximately 10,700 deaths occurring. The pathogenesis of MM is still largely unclear, but several reports suggest that interaction of tumor cells with the bone marrow microenvironment and microRNAs (miRNAs) deregulation may play a role in the etiology and progression of MM. miRNAs are small non-coding RNAs capable of regulating protein expression by binding to mRNA, and have been implicated in the development of MM. First identified inside cells, miRNAs can also be detected in body fluids, including serum and plasma, and may be a valid biomarker. Few studies have investigated the agreement between circulating miRNAs and intracellular myeloma PC miRNAs at diagnosis. Methods: Using Nano-String nCounter technology we first performed a screening analysis on serum samples obtained from MM patients and healthy controls. We identified a candidate set of miRNAs differentially expressed in the serum of MM patients. The levels of these miRNA markers were validated by RT-PCR in both serum and bone marrow PCs from the same cohort. Agreement of the quantitative miRNA marker levels between sample types was evaluated using intraclass correlation coefficients (ICC) (both for normalized and log2 measures). Results: Thirty-nine MM patients (21 male, 18 female) with a median age of 72 years (range: 65 – 83) were included in the analysis. Most were ISS stage I or II (59% vs. 41% ISS stage III) and 39% were high risk according to FISH abnormalities – 21% of patients carried del17p, 24% t(4;14) and 5% t(14;16). Medians and ranges for lab markers were as follows: hemoglobin 10.0 g/dl (7.2 to 15.1), beta2-microglobulin 5.18 ug/ml (1.38 – 12.1), creatinine 0.94 mg/dl (0.65 – 2.49), CRP = 1.6 mg/dl (0.02 – 116.0). Nine age-matched healthy controls were also used for the analysis. After the screening analysis, the following miRNAs were differentially expressed between healthy subjects and MM patients in serum samples: miR-92a, miR-451, miR-19b, miR-21, miR-16, miR-25, miR-30a, and miR-126. There was no significant agreement or correlation between serum and myeloma cell samples using either untransformed as well as log2measures (all p>0.40) (Table 1). Conclusion: Our preliminary results suggest a difference between circulating miRNAs in myeloma patients from controls. This indicates that future studies are needed to better define the role of miRNAs in the peripheral blood as a prognostic and even diagnostic biomarker in myeloma. From our preliminary data it also appears that circulating miRNAs are not simply secreted into the peripheral blood by myeloma PCs as it seems that circulating miRNAs do not reflect those of myeloma PCs. Differential expression could be determined by other cells that can release and or modify their miRNA expression in response to MM. Ongoing studies are examining the origin and function of miRNAs in the peripheral blood. Disclosures: No relevant conflicts of interest to declare.

Published
2012
Full Text
View/download PDF

48. Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors

Author

Palumbo, Antonio, primary, Bringhen, Sara, additional, Cavalli, Maide, additional, Ria, Roberto, additional, Offidani, Massimo, additional, Patriarca, Francesca, additional, Nozzoli, Chiara, additional, Guglielmelli, Tommasina, additional, Benevolo, Giulia, additional, Callea, Vincenzo, additional, Zambello, Renato, additional, Pietrantuono, Giuseppe, additional, De Rosa, Luca, additional, Liberati, Anna Marina, additional, Crippa, Claudia, additional, Perrone, Giulia, additional, Ciambelli, Fabrizio, additional, Carella, Angelo Michele, additional, Palmieri, Salvatore, additional, Gilestro, Milena, additional, Magarotto, Valeria, additional, Petrucci, Maria Teresa, additional, Musto, Pellegrino, additional, Gaidano, Gianluca, additional, and Boccadoro, Mario, additional

Published
2010
Full Text
View/download PDF

49. Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.

Author

Palumbo, Antonio, primary, Bringhen, Sara, additional, Rossi, Davide, additional, Ria, Roberto, additional, Offidani, Massimo, additional, Patriarca, Francesca, additional, Nozzoli, Chiara, additional, Levi, Anna, additional, Guglielmelli, Tommasina, additional, Benevolo, Giulia, additional, Callea, Vincenzo, additional, Olivero, Barbara, additional, Morabito, Fortunato, additional, Grasso, Mariella, additional, Marasca, Roberto, additional, Rizzo, Manuela, additional, Falcone, Antonietta Pia, additional, Gottardi, Daniela, additional, Montefusco, Vittorio, additional, Musolino, Caterina, additional, Zambello, Renato, additional, Cangialosi, Clotilde, additional, Pietrantuono, Giuseppe, additional, Magarotto, Valeria, additional, Petrucci, Maria Teresa, additional, Musto, Pellegrino, additional, Ciccone, Giovannino, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, and Boccadoro, Mario, additional

Published
2009
Full Text
View/download PDF

50. Impact of Baseline Free Light Chain Ratio (rFLC) On Clinical Outcomes and Change in rFLC During Treatment in Patients with Relapsed/Refractory Multiple Myeloma Treated with Pegylated Liposomal Doxorubicin Plus Bortezomib or Bortezomib Alone.

Author

Magarotto, Valeria, primary, Londhe, Anil, additional, Lantz, Keith C., additional, Lowery, Colin, additional, Sonneveld, Pieter, additional, Bladé, Joan, additional, Harousseau, Jean-Luc, additional, and Orlowski, Robert Z., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results